Sarcopenia and Physical Activity Intervention: a Randomized-controlled Trial

Sponsor
Scientific Institute San Raffaele (Other)
Overall Status
Recruiting
CT.gov ID
NCT05071040
Collaborator
Istituto Ortopedico Galeazzi (Other)
198
1
2
32.4
6.1

Study Details

Study Description

Brief Summary

Sarcopenia is a pathophysiological process associated with aging and some metabolic conditions characterized by progressive muscle tissue loss, which may lead to loss of strength and performance and increased risk of falls and fractures, physical disability and premature death. With the present project the investigator aim to assess the effect of a feasible exercise program to improve muscle strength (primary outcome), and muscle volume and performance and other measures potentially associated with sarcopenia (secondary outcomes) in elderly and people living with HIV (PLWH) with sarcopenia. The investigators plan to enroll 98 elderly and 98 PLWH in a multicentric, 48-week, randomized, parallel-group, open label, superiority trial comparing the effect of a home-based and app-monitored strength exercise intervention versus no intervention. The investigators expect that participants who exercise will improve strength and other parameters and that improvement at week 12 and week 48 will be higher than in no-exercise controls.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Home-based physical activity
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
198 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Reduction of Sarcopenia Through a Home-based, App-monitored, Physical Exercise Intervention
Actual Study Start Date :
Feb 1, 2022
Anticipated Primary Completion Date :
Oct 15, 2022
Anticipated Study Completion Date :
Oct 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exercise group

Participants will follow a strength exercise program monitored through the use of a specifically designed smartphone application.

Behavioral: Home-based physical activity
Participants will follow a strength exercise program

No Intervention: Control group

Continue their daily routine without exercise prescription.

Outcome Measures

Primary Outcome Measures

  1. Muscle strenght improvement [Week 12]

    To assess the effect of exercise on muscle strength assess by the handgrip, in elderly people and PLWH, through comparison between an experimental and a control group.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Sedentary

  • 60 year-old in the elderly group or >50 year-old for the PLWH group;

  • with sarcopenia, as defined by both relative loss of muscle mass by bioimpedentiometry (BIA) and low muscle strength by handgrip

Exclusion Criteria:
  • Any disease requiring hospitalization in the 6 weeks before enrollment;

  • Medical conditions contraindicating the proposed exercise as established by a sport medicine specialist;

  • Current substance or alcohol abuse or use of drugs that may influence balance and coordination;

  • Not being able to walk without assistance and to perform the prescribed exercises as by protocol.

Contacts and Locations

Locations

Site City State Country Postal Code
1 IRCCS Ospedale San Raffaele Turro Milano Italy 20127

Sponsors and Collaborators

  • Scientific Institute San Raffaele
  • Istituto Ortopedico Galeazzi

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Paola Cinque, Principal Investigator, Scientific Institute San Raffaele
ClinicalTrials.gov Identifier:
NCT05071040
Other Study ID Numbers:
  • RF-2019-12370198
First Posted:
Oct 7, 2021
Last Update Posted:
May 10, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 10, 2022